As long as your putting yourself in the position of the buyer..what do you think Novartis shareholders would think of 15 billion of their money going to a company that can't grow the sales of the greatest drug this century at roughly 5x current price..are EU sales going to be that difficult to obtain...AMRN is damaged and needs to be sold...hopefully SOMEONE is interested at 15...in the meantime if JT can't get the job done is certainly looks like Fridays adjustments to compensation makes it look like he will be around for a long time...and the cash burn continues...it always easier to sell when someone is interested rather than pushing it on someone.
Bird, Solid analysis. $15 billion is my vague number as well. I think China will be worth more than $20 million a year. Other than that I agree with everything in your post. Let's hope we are right. Sleven,
Announcement of a timely ANDA submission to the FDA for a combo statin-Vascepa product(e.g. 20 mgms of statin combined with 1 gm of Vascepa) would help Amarin to reclaim its rightful U.S. market for branded Vascepa. Many patients with CVD are on multiple meds and taking one less med would be appreciated.
For those patients, who need a lower dose of a statin, a combo with 10 mgs of a Statin and 1 gm Of Vascepa could also be made available.
News 
Market Data 
Discover 
